Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00266656 · ClinicalTrials.gov registry record · Phase 4
Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 69
- Enrollment target
NCT00266656 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 69 participants.
The verdict
NCT00266656, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 69 participants
- Enrollment target
Study Summary
This is an extension study that will gather long-term data on the effect of early growth hormone (GH) treatment on adult height and other aspects of health and development in girls with Turner syndrome. The main purpose is to determine whether girls who received 2 years of GH treatment before 6 years of age achieve taller adult height than girls who were untreated during this time. The study will also look at middle ear and hearing function, and cognitive and behavioral development. Protocol completion is defined as attainment of height velocity less than or equal to 1.0 cm/year, or bone age greater than or equal to 15 years.
Interventions
- DRUG Humatrope
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2005-12 |
| Est. Completion | 2015-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00266656
The ClinicalTrials.gov registry entry for NCT00266656 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Humatrope is the first listed.
NCT00266656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00266656 about?
NCT00266656 is a clinical study titled "Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome". This is an extension study that will gather long-term data on the effect of early growth hormone (GH) treatment on adult height and other aspects of health and development in girls with Turner syndrome. The main purpose is to determine whether girls who received 2 years of GH treatment before 6 year...
What is the current status of trial NCT00266656?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 69 participants. The study started on 2005-12. Estimated completion is 2015-09.
What interventions are being tested in trial NCT00266656?
The interventions under investigation include: Humatrope (DRUG).
Who is sponsoring clinical trial NCT00266656?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.